Cardiovascular effects of CPU-23, a novel calcium channel blocker developed from a chinese medicinal herb

H. Dong, M. L. Earle, Christopher Triggle

Research output: Contribution to journalArticle

Abstract

To develop novel therapeutic agents based on lead compounds isolated from Chinese medicinal herbs, a series of benzyl-tetrahydroisoquinolines have been synthesized and screened. CPU-23, the most potent compound identified in this series, was found to inhibit KCl-induced contraction of rat aorta and displace [3H]nitrendipine binding in rat cerebral cortical membranes with similar potency. It also induced hypotension and bradycardia in the rat in vivo. In the present study, the cardiovascular effects of CPU-23 were further investigated by using the patch-clamp, tension and haemodynamic measurements. CPU-23 (1-10 uM) dose-dependently inhibited inward Ba2currents of single smooth muscle cells isolated from the rat tail artery and reduced concentration-response curves for KC1 and phenylephrine in isolated rings in the presence of extracellular Ca2+, with PD2 values 5.70 and 4.85, respectively. CPU-23 (10-30 juM) also inhibited norepinephrine-induced contraction from 40% of control to 23% and 14% (p 0.01 for both) in the absence of extracellular Ca2+. The profile of hemodynamic action of CPU-23 was similar to diltiazem. It induced a rapid onset and long-lasting decrease in left ventricular systolic pressure, maximal velocity of pressure increase, systolic blood pressure, diastolic blood pressure and heart rate. These data indicate that CPU-23 is a novel calcium channel blocker, which exerts anti-hypertensive and cardiac depressant effects due to its blocking actions primarily on voltage-dependent calcium channels and partially on receptor-operated calcium channels and calcium release from intracellular stores.

Original languageEnglish
Pages (from-to)150-151
Number of pages2
JournalProceedings of the Western Pharmacology Society
Volume40
Publication statusPublished - 1997
Externally publishedYes

Fingerprint

Calcium Channel Blockers
Medicinal Plants
Blood Pressure
Calcium Channels
Hemodynamics
Controlled Hypotension
Tetrahydroisoquinolines
Nitrendipine
Diltiazem
Anti-Arrhythmia Agents
Phenylephrine
Ventricular Pressure
Bradycardia
Antihypertensive Agents
Smooth Muscle Myocytes
Aorta
CPU 23
Tail
Norepinephrine
Arteries

ASJC Scopus subject areas

  • Pharmacology

Cite this

@article{6766acab83ed4dbf8c45cd1a2d4a4309,
title = "Cardiovascular effects of CPU-23, a novel calcium channel blocker developed from a chinese medicinal herb",
abstract = "To develop novel therapeutic agents based on lead compounds isolated from Chinese medicinal herbs, a series of benzyl-tetrahydroisoquinolines have been synthesized and screened. CPU-23, the most potent compound identified in this series, was found to inhibit KCl-induced contraction of rat aorta and displace [3H]nitrendipine binding in rat cerebral cortical membranes with similar potency. It also induced hypotension and bradycardia in the rat in vivo. In the present study, the cardiovascular effects of CPU-23 were further investigated by using the patch-clamp, tension and haemodynamic measurements. CPU-23 (1-10 uM) dose-dependently inhibited inward Ba2currents of single smooth muscle cells isolated from the rat tail artery and reduced concentration-response curves for KC1 and phenylephrine in isolated rings in the presence of extracellular Ca2+, with PD2 values 5.70 and 4.85, respectively. CPU-23 (10-30 juM) also inhibited norepinephrine-induced contraction from 40{\%} of control to 23{\%} and 14{\%} (p 0.01 for both) in the absence of extracellular Ca2+. The profile of hemodynamic action of CPU-23 was similar to diltiazem. It induced a rapid onset and long-lasting decrease in left ventricular systolic pressure, maximal velocity of pressure increase, systolic blood pressure, diastolic blood pressure and heart rate. These data indicate that CPU-23 is a novel calcium channel blocker, which exerts anti-hypertensive and cardiac depressant effects due to its blocking actions primarily on voltage-dependent calcium channels and partially on receptor-operated calcium channels and calcium release from intracellular stores.",
author = "H. Dong and Earle, {M. L.} and Christopher Triggle",
year = "1997",
language = "English",
volume = "40",
pages = "150--151",
journal = "Proceedings of the Western Pharmacology Society",
issn = "0083-8969",
publisher = "Western Pharmacology Society",

}

TY - JOUR

T1 - Cardiovascular effects of CPU-23, a novel calcium channel blocker developed from a chinese medicinal herb

AU - Dong, H.

AU - Earle, M. L.

AU - Triggle, Christopher

PY - 1997

Y1 - 1997

N2 - To develop novel therapeutic agents based on lead compounds isolated from Chinese medicinal herbs, a series of benzyl-tetrahydroisoquinolines have been synthesized and screened. CPU-23, the most potent compound identified in this series, was found to inhibit KCl-induced contraction of rat aorta and displace [3H]nitrendipine binding in rat cerebral cortical membranes with similar potency. It also induced hypotension and bradycardia in the rat in vivo. In the present study, the cardiovascular effects of CPU-23 were further investigated by using the patch-clamp, tension and haemodynamic measurements. CPU-23 (1-10 uM) dose-dependently inhibited inward Ba2currents of single smooth muscle cells isolated from the rat tail artery and reduced concentration-response curves for KC1 and phenylephrine in isolated rings in the presence of extracellular Ca2+, with PD2 values 5.70 and 4.85, respectively. CPU-23 (10-30 juM) also inhibited norepinephrine-induced contraction from 40% of control to 23% and 14% (p 0.01 for both) in the absence of extracellular Ca2+. The profile of hemodynamic action of CPU-23 was similar to diltiazem. It induced a rapid onset and long-lasting decrease in left ventricular systolic pressure, maximal velocity of pressure increase, systolic blood pressure, diastolic blood pressure and heart rate. These data indicate that CPU-23 is a novel calcium channel blocker, which exerts anti-hypertensive and cardiac depressant effects due to its blocking actions primarily on voltage-dependent calcium channels and partially on receptor-operated calcium channels and calcium release from intracellular stores.

AB - To develop novel therapeutic agents based on lead compounds isolated from Chinese medicinal herbs, a series of benzyl-tetrahydroisoquinolines have been synthesized and screened. CPU-23, the most potent compound identified in this series, was found to inhibit KCl-induced contraction of rat aorta and displace [3H]nitrendipine binding in rat cerebral cortical membranes with similar potency. It also induced hypotension and bradycardia in the rat in vivo. In the present study, the cardiovascular effects of CPU-23 were further investigated by using the patch-clamp, tension and haemodynamic measurements. CPU-23 (1-10 uM) dose-dependently inhibited inward Ba2currents of single smooth muscle cells isolated from the rat tail artery and reduced concentration-response curves for KC1 and phenylephrine in isolated rings in the presence of extracellular Ca2+, with PD2 values 5.70 and 4.85, respectively. CPU-23 (10-30 juM) also inhibited norepinephrine-induced contraction from 40% of control to 23% and 14% (p 0.01 for both) in the absence of extracellular Ca2+. The profile of hemodynamic action of CPU-23 was similar to diltiazem. It induced a rapid onset and long-lasting decrease in left ventricular systolic pressure, maximal velocity of pressure increase, systolic blood pressure, diastolic blood pressure and heart rate. These data indicate that CPU-23 is a novel calcium channel blocker, which exerts anti-hypertensive and cardiac depressant effects due to its blocking actions primarily on voltage-dependent calcium channels and partially on receptor-operated calcium channels and calcium release from intracellular stores.

UR - http://www.scopus.com/inward/record.url?scp=33748160195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748160195&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33748160195

VL - 40

SP - 150

EP - 151

JO - Proceedings of the Western Pharmacology Society

JF - Proceedings of the Western Pharmacology Society

SN - 0083-8969

ER -